Blueprint Medicines - BPMC Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 sell rating, 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.

16 analysts have issued 12-month price objectives for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they predict the company's share price to reach $72.68 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.

Blueprint Medicines' stock was trading at $43.81 at the beginning of 2023. Since then, BPMC stock has decreased by 0.8% and is now trading at $43.48.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our BPMC earnings forecast.

Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Thursday, February, 16th. The biotechnology company reported ($2.65) EPS for the quarter, beating the consensus estimate of ($2.73) by $0.08. The biotechnology company earned $38.78 million during the quarter, compared to analysts' expectations of $33.52 million. Blueprint Medicines had a negative net margin of 273.24% and a negative trailing twelve-month return on equity of 80.09%. The business's revenue for the quarter was down 63.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.99) EPS.

ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).

Blueprint Medicines updated its FY 2022 earnings guidance on Thursday, January, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $200.00 million-$200.00 million, compared to the consensus revenue estimate of $199.69 million.

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.19%), T. Rowe Price Investment Management Inc. (4.17%), Alliancebernstein L.P. (2.57%), JPMorgan Chase & Co. (2.42%), Macquarie Group Ltd. (2.19%) and Geode Capital Management LLC (1.86%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends.

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPMC stock can currently be purchased for approximately $43.48.

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.61 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis.

The company employs 495 workers across the globe.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.